1466 ACHIEVING THE “TRIFECTA” WITH PRIMARY CRYOTHERAPY FOR LOCALIZED PROSTATE CANCER: COLD REGISTRY DATA

Abstract

You have accessJournal of UrologyProstate Cancer: Localized1 Apr 20111466 ACHIEVING THE “TRIFECTA” WITH PRIMARY CRYOTHERAPY FOR LOCALIZED PROSTATE CANCER: COLD REGISTRY DATA Philippe E Spiess, Robert Given, and J Stephen Jones Philippe E SpiessPhilippe E Spiess Tampa, FL More articles by this author , Robert GivenRobert Given Norfolk, VA More articles by this author , and J Stephen JonesJ Stephen Jones Cleveland, OH More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.1401AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES In the present study, we evaluate the contemporary outcome of primary cryotherapy (with curative intent) for localized prostate cancer using the COLD (Cryo On-Line Data) Registry. Furthermore, we evaluate the therapeutic outcomes of primary cryotherapy in achieving the “trifecta” post-treatment defined as: ((1) achieving a nadir serum PSA < 0.6 ng/ml, (2) no urinary incontinence, and (3) ability to have sexual intercourse (with or without intervention). METHODS A prospectively, centrally collected secure online database has been developed of patients undergoing primary cryoablation for localized prostate cancer. Of the 4,321 patients undergoing primary cryotherapy included within the COLD Registry, complete medical records pertaining to continence status and serial PSA measurements post-treatment were available in 739 patients, with the therapeutic “trifecta” achieved in 364 of 739 patients (49.2%). RESULTS The mean age of patients at presentation was 66.9 years (+/− 7.6 years). The majority of patients had a baseline PSA < 10 ng/ml, a biopsy Gleason score < 8, and clinical stage < T2b (82%, 92%, and 66%; respectively). Most patients stratified in the low and intermediate (D'Amico) risk categories (25% and 49%, respectively). The 1, 2, and 5 year actuarial biochemical failure rates using the Phoenix definition (nadir + 2 ng/ml) were 94.1%, 91.2%, and 78.5%, respectively. At year following primary cryotherapy, urinary retention developed in 0.3% and urinary fistulas in 0.3% of patients. CONCLUSIONS The “trifecta” was achieved in close to half of the patients undergoing primary cryotherapy highlighting its therapeutic potential in the management of localized prostate cancer clearly however a prospective, long-term study is needed to validate these findings. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e587-e588 Peer Review Report Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Philippe E Spiess Tampa, FL More articles by this author Robert Given Norfolk, VA More articles by this author J Stephen Jones Cleveland, OH More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...